Retension Pharmaceuticals, Inc. (RTSN) stock
RTSNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 18, 2026
$13.89+2.48 (+21.74%)
Close on Nov 18, 2026Market cap $11.22MP/E –Yield –
Retension Pharmaceuticals cash
Cash and short-term investments held at the end of each period.
Retension Pharmaceuticals's cash was $9.19M at Sep 30, 2026. For fiscal 2025 it was $18.90M, up 130.9% from the year before.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $18.90M | +130.9% |
| FY2024 | Dec 31, 2024 | $8.19M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $9.19M | – |
| Q4 FY2025 | Dec 31, 2025 | $18.90M | – |
| Q3 FY2025 | Sep 30, 2025 | $19.42M | – |
| Q4 FY2024 | Dec 31, 2024 | $8.19M | – |
See a number that looks wrong?